Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperoxaluria Clear all
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 3 Interventional

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

NCT03847090
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
Reloxaliase, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
64
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting No phase listed Observational

Rare Kidney Stone Consortium Biobank

NCT02026388
View directory record Official record
Conditions
Primary Hyperoxaluria, Dent Disease, APRT Deficiency, Cystinuria
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Oxalate Absorption in Calcium Oxalate Stone Disease

NCT06331546
View directory record Official record
Conditions
Kidney Stone, Kidney Calculi, Urolithiasis, Urolithiasis, Calcium Oxalate, Nephrolithiasis, Nephrolithiasis, Calcium Oxalate, Oxalate Urolithiasis, Oxaluria, Healthy
Interventions
Low-oxalate diet, High-oxalate diet, soluble oxalate gut absorption test
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Withdrawn No phase listed Observational

International Registry for Primary Hyperoxaluria

NCT00875823
View directory record Official record
Conditions
Primary Hyperoxaluria, Nephrocalcinosis, Kidney Stones
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

NCT03095885
View directory record Official record
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
Interventions
Test Meal
Other
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Tucson, Arizona • Little Rock, Arkansas • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Withdrawn Phase 1 Interventional

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

NCT06138327
View directory record Official record
Conditions
Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions
BMN 255, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

NCT02547805
View directory record Official record
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones, Dietary Hyperoxaluria
Interventions
ALLN-177, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Pheonix, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting Phase 2 Interventional

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

NCT04580420
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1, End Stage Renal Disease
Interventions
DCR-PHXC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting Not applicable Interventional

O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease

NCT06330246
View directory record Official record
Conditions
Kidney Stone, Kidney Calculi, Urolithiasis, Urolithiasis, Calcium Oxalate, Nephrolithiasis, Nephrolithiasis, Calcium Oxalate, Oxalate Urolithiasis, Oxaluria
Interventions
Low oxalate fixed diets pre-colonization, Moderately high oxalate fixed diets pre-colonization, Colonization with Oxalobacter formigenes, Low oxalate fixed diets post-colonization, Moderately high oxalate fixed diets post-colonization
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting No phase listed Observational

Rare Kidney Stone Consortium Patient Registry

NCT00588562
View directory record Official record
Conditions
Primary Hyperoxaluria, Dent Disease, Cystinuria, APRT Deficiency
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
0 Years to 100 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2028
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients

NCT02794649
View directory record Official record
Conditions
Oxalate, Primary Hyperoxaluria, Microbiome
Interventions
Not listed
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

NCT06481150
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Tenapanor, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

NCT00283387
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Betaine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

NCT04152200
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1, Primary Hyperoxaluria
Interventions
Lumasiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

NCT03456830
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
ALLN-177, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxazyme in Patients With Hyperoxaluria

NCT01127087
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Oxazyme
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Kidney Axis in Enteric Hyperoxaluria

NCT05124886
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
Moderately High Oxalate (MOx) Diet
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Completed No phase listed Observational

Health-related Quality of Life in Rare Kidney Stone

NCT02124395
View directory record Official record
Conditions
Primary Hyperoxaluria, Cystinuria, Adenine Phosphoribosyl Transferase Deficiency, Dent Disease
Interventions
Health-related Quality of Life in Rare Kidney Stone Questionnaire
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
5 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

NCT03391804
View directory record Official record
Conditions
Enteric Hyperoxaluria, Primary Hyperoxaluria, Hyperoxalemia
Interventions
ALLN-177
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

NCT02503345
View directory record Official record
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
Interventions
ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 21, 2026, 10:42 PM EDT
Recruiting Phase 2 Interventional

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

NCT07587021
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1, PH1
Interventions
YOLT-203, Placebo
Genetic · Drug
Lead sponsor
YolTech Therapeutics Co., Ltd
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 10:42 PM EDT
Active, not recruiting No phase listed Observational

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 10:42 PM EDT